ShopTalk - Barbers as partners in health promotion: Reviewing social determinants of health, revisiting cardiology pioneers, and moving forward.

Social Determinants of Health (SDOH) like education, economic stability, social context, neighborhood environment, and healthcare access are increasingly recognized as major drivers of persistent health disparities, particularly among minority populations. Over the past year, studies have demonstrated and quantified the impact that certain SDOH have on uncontrolled blood pressure in Black and Hispanic adults compared to white adults. This underscores the need to view chronic diseases through a SDOH lens and implement multilevel interventions targeting these underlying social factors to achieve health equity. The ShopTalk initiative, based in Lakeland, Florida, represents a promising community-based approach to addressing SDOH and health disparities. It conducts health outreach in barbershops and hair salons - trusted community hubs where meaningful dialogues occur. Key components include providing health education materials, offering screenings, and facilitating physician connections, all at no cost. By leveraging these culturally-relevant spaces, ShopTalk simultaneously targets multiple SDOH domains like health literacy, economic barriers, neighborhood familiarity, and healthcare engagement. This builds upon the pioneering work of leaders like Dr. Elijah Saunders and Dr. Ronald Victor, who previously engaged social hubs to successfully raise hypertension awareness among underserved populations. As highlighted by Healthy People 2030's emphasis on SDOH, widespread implementation of such culturally-tailored community outreach shows potential for finally reducing longstanding disparities. Specific outcome measures are planned to optimize ShopTalk, with the goal of extracting generalizable insights to guide similar initiatives nationwide.

PCI vs. CABG in left main with multi-vessel coronary artery disease and diabetes: Case report.

This case challenges the conventional preference for coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) in patients with diabetes, left main coronary artery disease (LMCAD) and multivessel disease. Current guidelines generally recommend CABG, especially in the context of LMCAD. However, our case involves a male patient with diabetes with LMCAD and extensive multivessel disease who was successfully treated with PCI, demonstrating a favorable outcome. Despite the high-risk profile, including a SYNTAX score of 28, the PCI approach was selected. This decision was supported by evidence suggesting comparable outcomes between PCI and CABG in similar patients. Our case highlights the potential of PCI as not just a viable, but potentially superior alternative in specific high-risk patients with diabetes, contrary to the prevailing belief in favor of CABG for all patients with left main involvement.

Catheter Ablation as First-Line Therapy in Persistent Atrial Fibrillation: Patient Characteristics and Clinical Outcomes.

BACKGROUND: In patients with persistent atrial fibrillation (PerAF), antiarrhythmic drugs (AADs) are considered a first-line rhythm-control strategy, whereas catheter ablation is a reasonable alternative. OBJECTIVES: This study sought to examine the prevalence, patient characteristics, and clinical outcomes of patients with PerAF who underwent catheter ablation as a first or second-line strategy. METHODS: This multicenter observational study included consecutive patients with PerAF who underwent first-time ablation between January 2020 and September 2021 in 9 medical centers in the United States. Patients were divided into those who underwent ablation as first-line therapy and those who had ablation as second-line therapy. Patient characteristics and clinical outcomes were compared between the groups. RESULTS: A total of 2,083 patients underwent first-time ablation for PerAF. Of these, 1,086 (52%) underwent ablation as a first-line rhythm-control treatment. Compared with patients treated with AADs as first-line therapy, these patients were predominantly male (72.6% vs 68.1%; P = 0.03), with a lower frequency of hypertension (64.0% vs 73.4%; P < 0.001) and heart failure (19.1% vs 30.5%; P < 0.001). During a mean follow-up of 325.9 ± 81.6 days, arrhythmia-free survival was similar between the groups (HR: 1.13; 95% CI: 0.92-1.41); however, patients in the second-line ablation strategy were more likely to continue receiving AAD therapy (41.5% vs 15.9%; P < 0.001). CONCLUSIONS: A first-line ablation strategy for PerAF is prevalent in the United States, particularly in men with fewer comorbidities. More data are needed to identify patients with PerAF who derive benefit from an early intervention strategy.